The compound was awarded the status of orphan drug by the FDA in 2014 for malignant melanoma with the BRAFV600 mutation, and was then approved for combination treatment with vemurafenib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in November 2015. Here, BRAF is linked to metastatic melanoma.